Aim: To compare the efficacy and safety of Labetalol and methyldopa in hypertensive disorder of pregnancy. Materials and Methods: This perspective randomized study was carried out in the department of Obstetrics and Gynecology, Kurji Holy Family Hospital, Patna, Bihar, India from November 2015 to November 2017. All the patients of blood pressure  150/100 mm of Hg above 20 weeks of gestations. Results: We evaluated 100 patients. There was significant fall in mean arterial pressure [MAP] after treatment in both labetalol (98.51) and methyldopa (102.72) group but reduction was more in labetalol group. Mean gestational age in L group was 33.76 weeks and in M group was 34.21 weeks. So in prolongation of pregnancy and vaginal delivery labetalol came forward. They were less no. of caesarean section and reduced maternal and fetal morbidity. Conclusion: Labetalol is more advantageous than methyldopa in terms of better and quicker control of blood pressure. The maternal and fetal morbidity was much lower in labetalol treated cases fetal outcome was much better and it showed fewer side effects.